

22 November 2023

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**Successful Completion of Institutional Entitlement Offer**

Healius Limited (ASX:HLS) (**Healius**) is pleased to announce the successful completion of the fully underwritten institutional component of its 1 for 3.65 pro-rata accelerated non-renounceable entitlement offer (**Institutional Entitlement Offer**) of new fully paid ordinary shares (**New Shares**) as announced on Monday, 20 November 2023 (**Entitlement Offer** or **Equity Raising**).

The Institutional Entitlement Offer raised a total of approximately A\$154 million at A\$1.20 per New Share (**Offer Price**). The Institutional Entitlement Offer was well supported by existing Healius institutional shareholders with approximately 92% of entitlements available to eligible institutional shareholders taken up.

Entitlements not taken up by eligible institutional shareholders and entitlements of ineligible institutional shareholders were sold at the A\$1.20 Offer Price.

Settlement of the New Shares issued as part of the Institutional Entitlement Offer is expected to occur on Thursday, 30 November 2023, with the issue of those New Shares expected to occur and ordinary trading to commence on Friday, 1 December 2023.

The New Shares will rank equally with existing shares on issue. Healius has requested its trading halt be lifted and for its shares to recommence trading from market open today. ¹

Retail Entitlement Offer

The fully underwritten retail component of the Entitlement Offer (**Retail Entitlement Offer**) will raise approximately A\$33 million.

Eligible retail shareholders in Australia and New Zealand as at 7:00pm (Sydney time) on Thursday, 23 November 2023 (**Record Date**) will be invited to participate in the Retail Entitlement Offer at the same Offer Price and offer ratio as under the Institutional Entitlement Offer.

¹ ASX has confirmed that, as a result of the off-market takeover bid (**Takeover Offer**) from Australian Clinical Labs Limited (**ACL**), the New Shares will be issued under a separate ticker, expected to be 'HLSNB'. The New Shares will trade separately from the main class of Healius shares (unless the Takeover Offer lapses or ACL obtains relief from ASIC to extend the Takeover Offer to the New Shares). When the Takeover Offer ends or if ACL obtains relief from ASIC to extend the Takeover Offer to the New Shares, ASX will fold the New Shares into the main class of Healius shares. The Takeover Offer is currently scheduled to end on 29 February 2024.

The Retail Entitlement Offer will open on Tuesday, 28 November 2023 and close at 5:00pm (Sydney time) on Thursday, 7 December 2023. Further information about the Retail Entitlement Offer will be set out in a retail offer booklet (**Retail Offer Booklet**) which Healius expects to lodge with ASX and despatched or otherwise made available on Tuesday, 28 November 2023. Eligible retail shareholders are encouraged to read the Retail Offer Booklet in its entirety, in particular, the risk factors, and should seek financial advice if they are uncertain of whether or not to participate. Eligible retail shareholders can choose to take up all, part or none of their entitlement.

Eligible retail shareholders that take up their full entitlement may also apply for additional New Shares in excess of their entitlement (up to 25% of their entitlement and subject to scale-back, at Healius' discretion).

All Directors who are existing shareholders on the Record Date have committed to take up their pro rata entitlements under the Retail Entitlement Offer.

Further information

Further information regarding the Entitlement Offer is contained in the investor presentation released to ASX on Monday, 20 November 2023.

Nothing in this announcement constitutes legal, tax or other advice. You should seek appropriate professional advice before making any investment decision.

Entitlement Offer timetable²

Event	Date (Sydney time)
Trading Halt, Announcement of Equity Raising	Monday, 20 November 2023
Institutional Entitlement Offer bookbuild	Monday, 20 November 2023 – Tuesday, 21 November 2023
Announcement of results of the Institutional Entitlement Offer	Wednesday, 22 November 2023
Healius shares recommence trading	Wednesday, 22 November 2023
Entitlement Offer Record Date (7:00pm AEDT)	Thursday, 23 November 2023
Retail Entitlement Offer opens	Tuesday, 28 November 2023
Settlement of New Shares issued under the Institutional Entitlement Offer	Thursday, 30 November 2023
Allotment and trading of New Shares issued under the Institutional Entitlement Offer	Friday, 1 December 2023

² These dates are indicative only and are subject to change. Healius, reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to amend this indicative timetable. In particular, Healius reserves the right to extend the Equity Raising timetable and to withdraw or vary the Entitlement Offer without prior notice. Any extension of the Equity Raising timetable will have a consequential effect on the date for the allotment and issue of New Shares. Healius will consult with the underwriter in relation to any proposed change to this indicative timetable and any such change will require the consent of the underwriter.

Retail Entitlement Offer closes (5:00pm AEDT)	Thursday, 7 December 2023
Announcement of results of the Retail Entitlement Offer	Tuesday, 12 December 2023
Settlement of New Shares issued under the Retail Entitlement Offer	Wednesday, 13 December 2023
Allotment of New Shares issued under the Retail Entitlement Offer	Thursday, 14 December 2023
Commencement of trading of New Shares issued under the Retail Entitlement Offer	Friday, 15 December 2023

ENDS

The release of this announcement has been authorised by the Board.

For further information contact:

Market and analysts: Janet Payne Group Executive, Corporate Affairs Mobile: +61 409 995 517	Media: Andrew Butcher Bespoke Approach Mobile: +61 400 841 088
---	--

For over 30 years Healius has been one of Australia's leading healthcare companies, committed to supporting quality, affordable and accessible healthcare for all Australians. Today, Healius has two core diagnostics businesses, pathology and imaging. Through its unique footprint of centres and its 10,500 employees, Healius provides Australia-wide specialty diagnostic services to consumers and their referring practitioners.

Important Information

This announcement does not constitute financial product advice and does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent financial advice before making any investment decision.

Not for Release or Distribution in the United States

This announcement has been prepared for publication in Australia and may not be released or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any jurisdiction in which such an offer would be unlawful. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act"), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the entitlements may not be taken up or exercised by, and the New Shares may not be offered or sold, directly or indirectly, in the United States or to any person acting for the account or benefit of a person in the United States (to the extent that the person holds shares for the account or benefit of a person in the United States).